Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials

Journal of Cystic Fibrosis

Volumn 10, Issue SUPPL. 2, 2011, Pages

  Bilton, D ^a   Canny, G ^b   Conway, S ^c   Dumcius, S ^d   Hjelte, L ^e   Proesmans, M ^f   Tummler B ^g   Vavrova, V ^h   De Boeck, K ^f  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d VILNIUS UNIVERSITY   (Lithuania)

^e Karolinska Stockholm CF Centre   (Sweden)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Consensus; Cystic fibrosis; Definition; Outcome parameters; Pulmonary exacerbation

Indexed keywords

ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; CYSTIC FIBROSIS; DISEASE EXACERBATION; HUMAN; LUNG DISEASE; PHYSICIAN; PRACTICE GUIDELINE; PULMONARY EXACERBATION; SCORING SYSTEM; SYMPTOMATOLOGY;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; DISEASE PROGRESSION; EUROPE; HUMANS; PNEUMONIA, BACTERIAL;

EID: 79958077769     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/S1569-1993(11)60012-X     Document Type: Article

References (9)

1. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001, 153(4):345-352.
2. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002, 121(1):64-72.
3. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized re-combinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994, 331(10):637-642.
4. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999, 340(1):23-30.
5. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290(13):1749-1756.
6. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006, 354(3):229-240.
7. Dakin C, Henry RL, Field P, Morton J Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 2001, 31(6):436-442.
8. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001, 139(3):359-365.
9. Rabin HR, Butler SM, Wohl ME, et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004, 37(5):400-406.